QGEN vs. ACAD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Diagnostics now outperform Life Sciences due to academic funding cuts, making Qiagen's defensive profile more attractive in the current market. Qiagen offers stable growth, high profitability, and low leverage, providing a resilient investment option amid sector volatility and macroeconomic uncertainty. While Qiagen is a strong short-term buy, investors should also consider peers like SysMex, BioMerieux, and CellaVision for diversification and growth potential.
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q2 2025 Earnings Conference Call August 6, 2025 9:30 AM ET Company Participants John Gilardi - Vice President of Corporate Communications & Investor Relations Roland Sackers - CFO, MD & Member of Management Board Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Aisyah Noor - Morgan Stanley, Research Division Casey Rene Woodring - JPMorgan Chase & Co, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Harry MacKinnon Gillis - Joh.
Qiagen (QGEN) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Matches Q2 Earnings Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.6 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.57 per share a year ago.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN or EXAS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Qiagen (QGEN) or Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, QIAGEN N.V. (QGEN) is looking like an interesting pick, as it just reached a key level of support.
Here's Why Qiagen (QGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
